Dako Denmark A/S : Dako enters collaboration with Eli Lilly and Company for development of companion diagnostics

 Dako Denmark A/S : Dako enters collaboration with Eli Lilly and Company for
                     development of companion diagnostics

GLOSTRUP, Denmark, Jan. 7, 2013 - Dako, an Agilent Technologies company,
announced today it has entered into a master framework agreement with Eli
Lilly and Company for the development of companion diagnostic tests to
identify patients who may be more likely to benefit from an investigational
oncology medicine currently under development by Lilly.

The agreement constitutes a framework for collaboration between Dako and Lilly
with a focus on the Lilly oncology pipeline.

"Building lasting partnerships is a cornerstone to Dako," says Lars Holmkvist,
CEO of Dako and senior vice president, Agilent. "I warmly welcome Lilly, and
I am excited about what we may accomplish together for the benefit of patients
worldwide. This agreement heralds our mutual commitment to fighting cancer." 

Companion diagnostics are increasingly in demand with the recognition that
personalized medicine may provide a way to improve patient care and manage
health-care costs by targeting treatments to individuals more likely to
benefit from specific therapies.

"Tailored therapies are a key component of Lilly's strategy of providing
improved outcomes for individual patients," says Greg Zdechlik, chief
operating officer, Diagnostics, Eli Lilly and Company. "We look forward to
collaborating with Dako in an effort to develop oncology companion diagnostics
for patients worldwide who are waiting."

Dako has a strong heritage of developing diagnostic tests in collaboration
with pharmaceutical companies. The collaboration with Lilly is another example
of Dako's position in the clinical diagnostics market as a strong partner for
developing diagnostic tests for use in conjunction with medicines.

About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's reagents, instruments,
software and expertise to make accurate diagnoses and determine the most
effective treatment for cancer patients. Dako, with 1,200 employees, operates
in more than 100 countries. Dako became part of Agilent Technologies on June
21, 2012. Information about Dako is available at www.dako.com.

About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.

EDITORIAL CONTACT:

Maia Fredtoft Søchting, Dako
+45 25 46 10 83
maia.sochting@dako.com

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Dako Denmark A/S via Thomson Reuters ONE
HUG#1668620